NA Molodecky, IS Soon, DM Rabi et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review Gastroenterology 142 2012 46 54 e42.
M Neovius, EV Arkema, P Blomqvist et al. Patients with ulcerative colitis miss more days of work than the general population, even following colectomy Gastroenterology 144 2013 536 543
JE Everhart, CE Ruhl Burden of digestive diseases in the United States part I: overall and upper gastrointestinal diseases Gastroenterology 136 2009 376 386
B Khor, A Gardet, RJ Xavier Genetics and pathogenesis of inflammatory bowel disease Nature 474 2011 307 317
BS Kirschner Ulcerative colitis in children Pediatr Clin North Am 43 1996 235 254
B Moum, A Ekbom, MH Vatn et al. Inflammatory bowel disease: re-evaluation of the diagnosis in a prospective population based study in south eastern Norway Gut 40 1997 328 332
A Pera, P Bellando, D Caldera et al. Colonoscopy in inflammatory bowel disease. Diagnostic accuracy and proposal of an endoscopic score Gastroenterology 92 1987 181 185
J Satsangi, MS Silverberg, S Vermeire et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications Gut 55 2006 749 753
MS Silverberg, J Satsangi, T Ahmad et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology Can J Gastroenterol 19 suppl A 2005 5 36
BB Crohn, L Ginzburg, GD Oppenheimer Regional ileitis; a pathologic and clinical entity JAMA 99 1932 1323 1329
MS Silverberg, L Mirea, SB Bull et al. A population- and family-based study of Canadian families reveals association of HLA DRB1∗0103 with colonic involvement in inflammatory bowel disease Inflamm Bowel Dis 9 2003 1 9
AP Cuthbert, SA Fisher, MM Mirza et al. The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease Gastroenterology 122 2002 867 874
T Ahmad, A Armuzzi, M Bunce et al. The molecular classification of the clinical manifestations of Crohn's disease Gastroenterology 122 2002 854 866
SR Brant, MF Picco, JP Achkar et al. Defining complex contributions of NOD2/CARD15 gene mutations, age at onset, and tobacco use on Crohn's disease phenotypes Inflamm Bowel Dis 9 2003 281 289
I Cleynen, JR Gonzalez, C Figueroa et al. Genetic factors conferring an increased susceptibility to develop Crohn's disease also influence disease phenotype: results from the IBDchip European Project Gut 62 2013 1556 1565
EG de la Concha, M Fernandez-Arquero, G Lopez-Nava et al. Susceptibility to severe ulcerative colitis is associated with polymorphism in the central MHC gene IKBL Gastroenterology 119 2000 1491 1495
M Economou, TA Trikalinos, KT Loizou, EV Tsianos, JPA Ioannidis Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: a meta analysis Am J Gastroenterol 99 2004 2393 2404
B Newman, MS Silverberg, X Gu et al. CARD15 and HLA DRB1 alleles influence susceptibility and disease localization in Crohn's disease Am J Gastroenterol 99 2004 306 315
A Dignass, JO Lindsay, A Sturm et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management J Crohns Colitis 6 2012 991 1030
A Dignass, G Van Assche, JO Lindsay et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management J Crohns Colitis 4 2010 28 62
C Mowat, A Cole, A Windsor et al. Guidelines for the management of inflammatory bowel disease in adults Gut 60 2011 571 607
SB Hanauer, BG Feagan, GR Lichtenstein et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial Lancet 359 2002 1541 1549
SB Hanauer, WJ Sandborn, P Rutgeerts et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial Gastroenterology 130 2006 323 333
W Reinisch, WJ Sandborn, DW Hommes et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial Gut 60 2011 780 787
P Rutgeerts, WJ Sandborn, BG Feagan et al. Infliximab for induction and maintenance therapy for ulcerative colitis N Engl J Med 353 2005 2462 2476
WJ Sandborn, G van Assche, W Reinisch et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis Gastroenterology 142 2012 257 265 e1-3.
BG Feagan, P Rutgeerts, BE Sands et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis N Engl J Med 369 2013 699 710
WJ Sandborn, BG Feagan, P Rutgeerts et al. Vedolizumab as induction and maintenance therapy for Crohn's disease N Engl J Med 369 2013 711 721
AD Frolkis, J Dykeman, ME Negron et al. Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies Gastroenterology 145 2013 996 1006
IC Solberg, I Lygren, J Jahnsen et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study) Scand J Gastroenterol 44 2009 431 440
IC Solberg, MH Vatn, O Hoie et al. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study Clin Gastroenterol Hepatol 5 2007 1430 1438
L Jostins, S Ripke, RK Weersma et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease Nature 491 2012 119 124
JE Lennard-Jones Classification of inflammatory bowel disease Scand J Gastroenterol Suppl 170 1989 2 6 discussion 16-19.
P Goyette, G Boucher, D Mallon et al. High-density mapping of the MHC identifies a shared role for HLA-DRB1∗01:03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis Nat Genet 7 2015 172 179
S Purcell, B Neale, K Todd-Brown et al. PLINK: a tool set for whole-genome association and population-based linkage analyses Am J Hum Genet 81 2007 559 575
L Jostins, AP Levine, JC Barrett Using genetic prediction from known complex disease loci to guide the design of next-generation sequencing experiments PLoS One 8 2013 e76328
JC Barrett, S Hansoul, DL Nicolae et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease Nat Genet 40 2008 955 962
WA Faubion Jr, EV Loftus Jr, WS Harmsen et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study Gastroenterology 121 2001 255 260
J Halfvarson, L Bodin, C Tysk et al. Inflammatory bowel disease in a Swedish twin cohort: a long-term follow-up of concordance and clinical characteristics Gastroenterology 124 2003 1767 1773
L Henckaerts, K Van Steen, I Verstreken et al. Genetic risk profiling and prediction of disease course in Crohn's disease patients Clin Gastroenterol Hepatol 7 2009 972 980 e2.
PT Donaldson, JM Farrant, ML Wilkinson et al. Dual association of HLA DR2 and DR3 with primary sclerosing cholangitis Hepatology 13 1991 129 133
A Spurkland, S Saarinen, KM Boberg et al. HLA class II haplotypes in primary sclerosing cholangitis patients from five European populations Tissue Antigens 53 1999 459 469
EV Loftus Jr, GC Harewood, CG Loftus et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis Gut 54 2005 91 96
ML Hamshere, MC O'Donovan, IR Jones et al. Polygenic dissection of the bipolar phenotype Br J Psychiatry 198 2011 284 288
GB Chen, SH Lee, MJ Brion et al. Estimation and partitioning of (co)heritability of inflammatory bowel disease from GWAS and immunochip data Hum Mol Genet 23 2014 4710 4720
XC Morgan, TL Tickle, H Sokol et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment Genome Biol 13 2012 R79
